Adverse events of common psychiatric medications: an umbrella review

Size: px
Start display at page:

Download "Adverse events of common psychiatric medications: an umbrella review"

Transcription

1 Adverse events of common psychiatric medications: an umbrella review Katrina Bartellas, 1 Thomas Bajorek 1 Sarah Stockton, 1 Stefan Leucht, 2 Andrea Cipriani, 1 Seena Fazel 1 1 Department of Psychiatry, University of Oxford; 2 Department of Psychiatry and Psychotherapy, University of Munich, Germany. Corresponding author: Professor Seena Fazel Department of Psychiatry University of Oxford Warneford Hospital OXFORD OX3 7JX seena.fazel@psych.ox.ac.uk 1

2 Condition or domain being studied In 2014, there were approximately 537 million dispensed prescriptions of psychiatric medications in the United States (IMS, 2015). Psychiatric medications were prescribed more than almost every other therapeutic class of medications, second only to antihypertensives (705 million dispensed prescriptions). Furthermore, IMS Institute for Healthcare Informatics estimates that in 2014 with a figure of US$23.1 billion that more money was spent on psychiatric medications in the United States than almost any other therapeutic class, ranking third only to antidiabetic medications (US$ 32.2 Bn) and oncological medications (US$ 32.6 Bn). The World Health Organization states that psychotropic medications have the ability to ameliorate symptoms, reduce disability, shorten the course of many disorders, and prevent relapse (WHO, 2009). Certainly, psychopharmacotherapy can play a pivotal role in the treatment and management of psychiatric illness. The major classes of psychiatric medications include antidepressants, antipsychotics, stimulants, anxiolytics and mood stabilizers. Antidepressants are mainly used to treat moderate to severe depressive illness, severe anxiety, panic attacks, obsessive compulsive disorders, chronic pain, eating disorders and post-traumatic stress disorders. The main types of antidepressants include selective serotonin reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors, noradrenaline and specific serotoninergic antidepressants, tricyclic antidepressants and monoamine oxidase inhibitors. Antipsychotics are the main treatment for schizophrenia and are used for a wide variety of other psychiatric disorders. This class of medications is divided into typical (or first generation) antipsychotics and atypical (or second generation) antipsychotics. Stimulants are primarily prescribed to treat attention deficit hyperactivity. Due to their addictive profile, however, misuse and diversion are common problems experienced with prescribed 2

3 stimulant medications (Wilens et al., 2008). Anxiolytics are primarily used in the treatment of anxiety disorders. Benzodiazepines are hypnotic and anxiolytic agents primarily used to treat insomnia and acute anxiety. Mood stabilizers are primarily used in the treatment of bipolar disorders. Many AE, ranging from mild to severe, have been linked to psychiatric medications. In fact, before clozapine was developed, the ability of an agent to induce extrapyramidal symptoms validated its potential as an effective antipsychotic medication (Divac et al., 2014). Notably, a basic principle of prescribing pharmacological treatment is to inform the patient of any potential AE and on how to manage them should they occur (WHO, 2009). AE may be distressing or even frightening to patients yet are often underreported (Parker, C., 2012). As a response and solution to this problem, national systems have been developed in certain countries, such as the UK s Yellow Card Scheme, so that patients may be accountable to document any AE, especially those that are unprecedented or pose a serious health risk. The Yellow Card Scheme explains that any information provided by the public may help to identify previously unrecognised side effects, and thereby improve the safe use of medicines (MHRA, 2016). The documentation of AE for psychiatric medications is particularly important given not only the volume but the growth of dispensed prescriptions of this therapeutic class each year (IMS, 2015). There has been progress in terms of the output of systematic reviews and meta-analyses in the literature on AE but it is still fragmented. The Cochrane Database of Systematic Reviews has published comprehensive data on AE in numerous systematic reviews that focus on individual anti-depressive agents such as venlafaxine, escitalopram and duloxetine among others (Cipriani et al., 2007; Cipriani et al., 2010; Cipriani et al., 2012). Also, in contrast to focusing on a particular agent certain meta-analyses have pre-specified one or two AE of psychiatric 3

4 medications to analyze such as insomnia and somnolence (Alberti et al., 2015), dizziness (Thorlund et al, 2015), upper gastro intestinal bleeding (Jiang et al., 2015) and suicidal behavior and ideation (Hammad et al., 2006). The most comprehensive review identified to date that has accomplished a similar objective to our own analyzed the AE of antipsychotics, antidepressants and mood stabilizers on the risk for physical diseases in individuals with schizophrenia, depression and bipolar disorder (Correll et al., 2015). We want to build on the work of Correll et al. by centralizing the data on AE for clinicians and patients, however, we will undertake a wider search in order to include all relevant AE (not exclusively limited to physical diseases) and all classes of psychiatric medications. In 2015, Leucht et al. emphasized the importance of synthesizing the growing clinical literature on medications to provide practitioners with greater insight into this complex field (Leucht et al., 2015). We aim to achieve this outcome with our umbrella review on the AE of the most commonly prescribed psychiatric medications. Although the umbrella review research design is relatively new and has many limitations, it is becoming more widely adopted in the literature (Ioannidis, 2009). Umbrella reviews may analyze multiple treatments in contrast to a traditional systematic review or meta-analysis that focuses on a single treatment comparison or outcome. To our knowledge, there is no umbrella review to date synthesizing and analyzing the clinical data on the AE of the most commonly prescribed psychiatric medications across classes and diagnoses. This type of analysis, due to its large scale, may provide greater insights into the strengths and limitations of the literature and will aim to aid clinicians and patients who are weighing various treatment options. 4

5 The outcome to be examined is any AE reported in a meta-analysis focused on one or more of the interventions specified in our inclusion criteria. Our preliminary search using only the ten most commonly prescribed psychiatric medications yielded meta-analyses on the following AEs: suicidal behavior or ideation, insomnia, somnolence, falls, all cause mortality, upper gastro intestinal bleeding, hostility, major adverse cardiovascular events, nausea and dizziness. The former list is not exhaustive. Given that data on AE for individual psychiatric medications may be challenging to access, we decided against defining upfront a specific range of outcomes to be analyzed. Alternatively, we will look to include any AE that we find in the results section during our search. We will include the prevalence rates and effect sizes for the most relevant and important AE in our results, however, we will include a comprehensive list of the prevalence rates and effect sizes for all AE retrieved in the appendix. Review question(s) The aim of this umbrella review is to compare the prevalence rates and effect sizes of adverse events (AE) among the most common psychiatric medications. Searches Searches for published meta-analyses will be undertaken in the following electronic databases: CDSR, DARE, Embase, Medline, PreMedline, PsycINFO and PubMed. Studies will be identified by combining search terms for each drug with generic and specific adverse events and a study design limit for systematic reviews and meta-analyses. The following terms will eb used: antidepressive agents; antidepressive agents, second generation; antidepressive agents, tricyclic; serotonin uptake inhibitors; serotonin and noradrenaline reuptake inhibitors; amitriptyline; 5

6 bupropion; citalopram; citalopram; clomipramine; desvenlafaxine succinate; duloxetine hydrochloride; fluoxetine; paroxetine; sertraline; trazodone; venlafaxine hydrochloride; antipsychotic agents; aripiprazole; chlorpromazine; clozapine; fluphenazine; haloperidol; quetiapine fumarate; risperidone; anticonvulsants; carbamazepine; lithium carbonate; lithium; valproic acid; central nervous system stimulants; lisdexamfetamine dimesylate; methylphenidate; amphetamines; anti anxiety agents; buspirone; hydroxyzine; benzodiazepines; alprazolam; diazepam; lorazepam; "drug-related side effects and adverse reactions"; dizziness; nausea; suicide; suicide, attempted; suicidal ideation; hostility; mortality; "sleep initiation and maintenance disorders"; "disorders of excessive somnolence"; accidental falls; gastrointestinal hemorrhage; cardiovascular diseases; "meta-analysis as topic"; review literature as topic"; observational study; placebo; prevalence; randomized controlled trial; randomized controlled trial (topic). No date or language restrictions will be applied. The electronic database search will be supplemented by a manual search of reference lists from relevant studies. We will also undertake a search for unpublished meta-analyses by searching PROSPERO. Types of studies Meta-analyses of randomized controlled trials (RCTs) based on a systematic review of the literature and comparing with placebo will be included. Observational studies will be included for a separate comparative analysis. Meta-analyses comprised of more than 25% quasirandomized controlled trials or meta-analyses based on a non-systematic search strategy (for instance, pooled analyses of RCTs carried out by the drug manufacturer) will be excluded. Network meta-analyses will be excluded as network meta-analyses do not exist for every agent 6

7 that meets our inclusion criteria. Results without systematic review or meta-analysis in the title or abstract will be excluded. Participants/ population We will include participants of both sexes and any setting (either inpatients or outpatients) who were prescribed one of the psychiatric medications that met our intervention inclusion criteria. We will include both patient populations who are taking the medications for psychiatric and nonpsychiatric disorders. Meta-analyses of specific subgroups (i.e. pediatric or older adult population) will be excluded. Interventions We will include meta-analyses that evaluate one or more of the most commonly prescribed psychiatric medications in the United States in 2013 as reported by IMS Health. Our preliminary search included the ten most commonly prescribed medications-eight of which were primarily antidepressants and two of which were primarily benzodiazepines. Resultantly, the scope was limited so we expanded the list to include the twenty-five most commonly prescribed medications. We merged the following pairs of similar medications into single categories: bupropion HCL XL and bupropion HCL SR W; methylphenidate ER and generic methylphenidate; amphetamine salts ER and generic amphetamine salts. The updated version of the list comprises of the following pharmacological interventions: alprazolam, sertraline, citalopram, fluoxetine, lorazepam, trazodone, escitalopram, duloxetine, bupropion, venlafaxine, diazepam, paroxetine, quetiapine, risperidone, lisdexamfetamine, methylphenidate, aripiprazole, buspirone, hydroxyzine, olanzapine, amphetamine salts and desvenlafaxine. The psychotropic 7

8 medications included in the updated list belong to the following categories: antidepressants, anxiolytics, stimulants, antipsychotics and mood stabilizers. We will also include lithium, valproate, amitriptyline, clomipramine, fluphenazine, haloperidol, carbamazepine, clozapine and chlorpromazine to the list of medications as they are commonly used agents that are also included in the World Health Organization Essential Medicine List. Meta-analyses of depot medications will be included. If our search yields insufficient data on AE of individual psychiatric medications, we will redefine our intervention inclusion criteria to examine classes of medication. No restriction will be placed on timing, dose and duration, however, papers that focused on overdose and meta-analyses of augmentation or combination therapy will be excluded. Comparator(s)/ control Placebo will be the comparator for all meta-analyses of RCTs. Outcome(s) Prevalence rates and effect sizes for AE as presented as relative risks. Data extraction (selection and coding) Two researchers (KB and TB) will independently extract data retrieved by the search. If the reviewers agree that the meta-analysis does not meet eligibility criteria, we will exclude it. All disagreements will be resolved through discussion, and in case of persistent disagreement, by a third member of the reviewing team. 8

9 Risk of bias (quality) assessment We will assess the quality of the included meta-analyses using the AMSTAR measurement tool. Where inadequate details of the AMSTAR score is provided, we will contact the authors to obtain further information. Strategy for data synthesis We will perform a descriptive analysis for each meta-analysis. Specifically, we will provide a table that includes the first author s family name, title of the meta-analysis, publication year, sample size, patient characteristics, time to exposure to treatment and primary outcomes. Our preliminary search using only the ten most commonly prescribed psychiatric medications yielded meta-analyses on the following AEs: suicidal behavior or ideation, insomnia, somnolence, falls, all-cause mortality, upper gastro intestinal bleeding, hostility, major adverse cardiovascular events, nausea and dizziness. The results provided a framework summarizing the effects of antidepressants because eight of the ten medications searched were antidepressants. No AE common to antipsychotics (i.e. extra pyramidal effects) were found in the preliminary search. We recognize that the list of interventions used is biased given that they were the medications prescribed the most in In order for our meta-review to be fully representative of all classes of psychotropic agents we decided to include the top twenty-five instead of the top ten most commonly prescribed medications and to add medications for mental and behavioural disorders from the WHO Essential Medicine List. As a result, our final list includes not only antidepressants, but also anxiolytics, stimulants, mood stabilizers and antipsychotics. Also, the preliminary search yielded no results for the benzodiazepines searched (alprazolam and lorazepam). Therefore, a possible limitation of this meta-review may be an insufficient amount 9

10 of available data. Also, this reinforces the importance of our team searching for unpublished meta-analyses to supplement our database search. Certain pharmacological agents on the updated edited list are used to treat multiple psychiatric disorders. If during the study selection process we find that for the same intervention there are multiple meta-analyses that meet the inclusion criteria but focus on populations with different primary psychiatric diagnoses, we will subcategorize the meta-analyses in our table under intervention by diagnosis and examine each separately (see example of table below). Resultantly, we will be able to compare the effect sizes for the same AEs and the same intervention across psychiatric diagnoses. However, if during the study selection process we find multiple metaanalyses on both the same intervention and population, we will compare effect direction, significance and magnitude. The largest meta-analysis will be used in the main analysis so that the scope of AE under review will not be compromised. AE Intervention Effect estimates Meta-analysis A with primary diagnosis X Meta-analysis B with primary diagnosis Y The number of trials and patients included, the average duration of the studies in the metaanalyses, the proportion of patients with each AE, the relative risk, the absolute risk and the 95% confidence intervals (using both fixed- and random-effects models), I-squared statistics, as well 95% prediction intervals will be presented for each intervention. Furthermore, we will perform tests to determine the presence or absence of small study effects and excess significance bias. 10

11 The preliminary search illustrated methodological differences of published meta-analyses on AEs. Therefore, we will compare the effect sizes of AEs in meta-analyses comprising of RCTs using placebo with those comprising of observational studies. Also, we will attempt to also calculate the Number Needed to Harm (NNH) for our primary outcome from the overall effect estimates. Analysis of subgroups or subsets We will conduct subgroup analyses using the following characteristics as possible sources of inconsistency and or heterogeneity: (i) (ii) (iii) (iv) Methodology (RCTs comparing with placebo and observational studies) Diagnosis Year of publication Sponsorship 11

12 References Alberti, S., et al. (2015). "Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis." J Clin Psychopharmacol 35(3): Cipriani, A., et al. (2012). "Duloxetine versus other anti-depressive agents for depression." Cochrane Database Syst Rev 10: Cd Cipriani, A. et al. (2010). Escitalopram versus other antidepressive agents for depression. The Cochrane Collaboration. The Cochrane Database Sys Rev: CD Cipriani, A., et al. (2007). "Venlafaxine versus other anti-depressive agents for depression." Cochrane Database Syst Rev 2: CD Correll, C, et al. (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14: Divac, N., et al. (2014). "Second-generation antipsychotics and extrapyramidal adverse effects." Biomed Res Int 2014: Hammad, T. A., et al. (2006). "Suicidality in pediatric patients treated with antidepressant drugs." Arch Gen Psychiatry 63(3): IMS Institute for Healthcare Informatics. (2015). Medicines Use and Spending Shifts. Retrieved on February 1, 2016 from ending_shifts/medicine-spending-and-growth_ pdf 12

13 Ioannidis, J. P. (2009). "Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses." CMAJ 181(8): Jiang, H. Y., et al. (2015). "Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis." Clin Gastroenterol Hepatol 13(1): e43. Leucht, S., et al. (2015). "How effective are common medications: a perspective based on metaanalyses of major drugs." BMC Med 13: 253. Medicines and Healthcare product Regulatory Agency. (2016). About Yellow Card. Retrieved February 1, 2016 from Parker, C. (2012). "Psychiatric effects of drugs for other disorders." Medicine 40(12): Thorlund, K. et al. (2015). Comparative efficacy and safety of levoctive serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. Journal of the American Geriatrics Society 63(5): Wilens, T., et al. (2008). Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child & Adolescent Psychiatry 47(1): World Health Organization. (2009). Pharmacological treatment of mental disorders in primary health care. Retrieved on January 15, 2016 from 13

Introduction to Drug Treatment

Introduction to Drug Treatment Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical

More information

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XIV, 2012 INDEX A Adderall Counterfeit, 31 addiction, internet CBT, 55 ADHD Adjunctive Guanfacine, 11 Counterfeit Adderall, 31 Developmental Trajectory and Risk Factors, 5 Dopamine Transporter Alterations, 14 Extended-Release

More information

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100

More information

Manual of Clinical Psychopharmacology

Manual of Clinical Psychopharmacology Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School

More information

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation

Medications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral

More information

Eligible Beneficiaries

Eligible Beneficiaries Therapeutic Class: Behavioral Health Medications for Adults Clinical Edit Number Long Description 4110 (May change) Quantity limit edit that is applied to atypical antipsychotics for claims identified

More information

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI

Psychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT

More information

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic

More information

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine

More information

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder

More information

Pediatric Psychopharmacology

Pediatric Psychopharmacology Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders

More information

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer

A Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

Depression. University of Illinois at Chicago College of Nursing

Depression. University of Illinois at Chicago College of Nursing Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors

More information

Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG

Medication management of anxiety & depression. Dr Katie Simpson GP Mental health lead East Berks CCG Medication management of anxiety & depression Dr Katie impson GP Mental health lead East Berks CCG NICE guidelines for Anxiety tepped Care RIs and NRIs in Anxiety disorders RI ertraline Citalopram Fluoxetine

More information

Medications and Children Disorders

Medications and Children Disorders Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for

More information

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines

More information

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford

Medication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant

More information

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally

More information

Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder

Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants

More information

Document Title Pharmacological Management of Generalised Anxiety Disorder

Document Title Pharmacological Management of Generalised Anxiety Disorder Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)

More information

AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE

AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE Topic AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE Scope 4.3.1 (a) Review question(s)

More information

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by

Medically Accepted Indications for Pediatric Use of Psychotropic Medications by Key: White Background: Medically Accepted Indication Yellow Backgroun: Medically Accepted Indication Status Not Ascertained Orange Background: Pediatric Indication cited, but not supported Red Background:

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Scope for Partial Update 1 Guideline title Anxiety: management of generalised anxiety disorder in adults in primary, secondary and community care (update)

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

PSYCHIATRY INTAKE FORM

PSYCHIATRY INTAKE FORM Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.

More information

Treatment Options for Bipolar Disorder Contents

Treatment Options for Bipolar Disorder Contents Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8

More information

Richard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA

Richard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA *We are not accepting any New Patients who are currently taking any controlled pain medications *We are *Note: not completion accepting of the any following New Patients paperwork who and Initial are Screening

More information

Anxiety Disorders.

Anxiety Disorders. Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

DISEASES AND DISORDERS

DISEASES AND DISORDERS DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related

More information

NorthSTAR. Pharmacy Manual

NorthSTAR. Pharmacy Manual NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics

More information

Psychobiology Handout

Psychobiology Handout Nsg 85A / Psychiatric Page 1 of 7 Psychobiology Handout STRUCTURE AND FUNCTION OF THE BRAIN Psychiatric illness and the treatment of psychiatric illness alter brain functioning. Some examples of this are

More information

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance

More information

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Antipsychotics medications are approved by the

More information

GUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS

GUIDELINES FOR THE USE OF PSYCHOACTIVE MEDICATIONS IN INDIVIDUALS WITH CO-OCCURRING SUBSTANCE USE DISORDERS City and County of San Francisco Mayor Gavin Newsom Department of Public Health Community Behavioral Health Services 1380 Howard Street 5 th Floor San Francisco, CA 94103 GUIDELINES FOR THE USE OF PSYCHOACTIVE

More information

Volume 4; Number 5 May 2010

Volume 4; Number 5 May 2010 Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated

More information

Class Update: Oral Antipsychotics

Class Update: Oral Antipsychotics Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database

Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database open access Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database Carol Coupland, 1 Trevor Hill, 1 Richard Morriss,

More information

Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder (PTSD)

Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder (PTSD) 1 Psychological and Pharmacological Treatments for Adults with Posttraumatic Stress Disorder (PTSD) This continuing education monograph examines the results of a comparative effectiveness review to assess

More information

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment

Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,

More information

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY

FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD OF ANXIETY 13 th Pearl Leibovitch Clinical Day November 18th, 2014 Mounir H. Samy, MD, FRCP(C) Associate Professor of Psychiatry McGill University (ret.) FROM MEDICATION TO MINDFULNESS: NEW INSIGHTS INTO THE WORLD

More information

Safe transfer of prescribing guidance

Safe transfer of prescribing guidance Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed

More information

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers.

Answer ALL questions. For each question, there is ONE correct answer. Use the answer grid provided for ALL your answers. CLINICAL THERAPEUTICS 7: PSYCHIATRY PHA-MHBY Time allowed: 2 hours UNIVERSITY OF EAST ANGLIA School of Pharmacy Main Series UG Examination 2013-2014 Part ONE Answer ALL questions. For each question, there

More information

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX

CHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,

More information

Things You Might Not Know About Psychotropic Medications But Wish You Did

Things You Might Not Know About Psychotropic Medications But Wish You Did Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and

More information

Mental illness A Broad Overview. Dr H Pathmanandam March 2017

Mental illness A Broad Overview. Dr H Pathmanandam March 2017 Mental illness A Broad Overview Dr H Pathmanandam March 2017 Introduction Mental disorders are common in primary and secondary care Many are not recognised and not treated Some receive unnecessary or inappropriate

More information

Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal. Alan Poling, Ph.D., BCBA-D Western Michigan University

Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal. Alan Poling, Ph.D., BCBA-D Western Michigan University Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal Alan Poling, Ph.D., BCBA-D Western Michigan University In a 2010 study of 60,641 children Mandell et al. found that: 56%

More information

Schedule FDA & literature based indications

Schedule FDA & literature based indications Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for

More information

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College

More information

Depression in adults: treatment and management

Depression in adults: treatment and management 1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations

More information

Guide to Psychiatric Medications for Children and Adolescents

Guide to Psychiatric Medications for Children and Adolescents Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists

More information

Study Guidelines for Quiz #1

Study Guidelines for Quiz #1 Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing

More information

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A

Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College

More information

PRESCRIBING GUIDELINES

PRESCRIBING GUIDELINES The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors

More information

South London and the Maudsley NHS Foundation Trust Medicines Formulary

South London and the Maudsley NHS Foundation Trust Medicines Formulary South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Disclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015

Disclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015 49th Annual Meeting Psychiatry for the Non-Psychiatry Specialist Jacintha Cauffield, PharmD, BCPS, CDE Associate Professor of Pharmacy Practice Lloyd L. Gregory School of Pharmacy Palm Beach Atlantic University

More information

For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013

For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please

More information

PSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX

PSYCHIATRY DRUG ALERTS, VOLUME XXVIII, 2014 INDEX A acamprosate ADHD Generic Methylphenidate Equivalence, 84 Methylphenidate in Pregnancy, 9 Stimulants in Pregnancy, 50 adverse effects Antidepressant-Induced Jitteriness, 94 Antidepressants and Sexual

More information

Mood Disorders.

Mood Disorders. Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner

More information

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole

More information

Psychiatry in Primary Care: What is the Role of Pharmacist?

Psychiatry in Primary Care: What is the Role of Pharmacist? Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure

More information

5 COMMON QUESTIONS WHEN TREATING DEPRESSION

5 COMMON QUESTIONS WHEN TREATING DEPRESSION 5 COMMON QUESTIONS WHEN TREATING DEPRESSION Do Antidepressants Increase the Possibility of Suicide? Will I Accidentally Induce Mania if I Prescribe an SSRI? Are Depression Medications Safe and Effective

More information

Depression & Anxiety in Adolescents

Depression & Anxiety in Adolescents Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with

More information

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17

More information

Smoking Cessation Pharmacotherapy Guidelines

Smoking Cessation Pharmacotherapy Guidelines Smoking Cessation Pharmacotherapy Guidelines INTRODUCTION This guideline is based on public health guidance 10 Smoking Cessation Services issued by the National Institute for Health and Clinical Excellence

More information

This initial discovery led to the creation of two classes of first generation antidepressants:

This initial discovery led to the creation of two classes of first generation antidepressants: Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out

More information

35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child

35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization

More information

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

MEDICATION ALGORITHM FOR ANXIETY DISORDERS Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON

More information

Presentation is Being Recorded

Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

Psychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson

Psychotropic Drug Therapy in Adults with Learning Disability. Steve Wilkinson Psychotropic Drug Therapy in Adults with Learning Disability Steve Wilkinson Outline and Aims of the Session Drug use in learning disability Two distinct areas of drug therapy I. Treatment of common psychiatric

More information

Recommendation 1: Diagnosis of Generalized Anxiety Disorder (IΙΙ-2)

Recommendation 1: Diagnosis of Generalized Anxiety Disorder (IΙΙ-2) Final GAD RECOMMENDATIONS & EVIDENCE Recommendation 1: Diagnosis of Generalized Anxiety Disorder (IΙΙ-2) It is recommended for general practitioners and other Primary Health Care doctors to consider the

More information

TITLE: Buspirone for the Treatment of Anxiety: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness

TITLE: Buspirone for the Treatment of Anxiety: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness TITLE: Buspirone for the Treatment of Anxiety: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness DATE: 03 May 2012 CONTEXT AND POLICY ISSUES Generalized Anxiety Disorder (GAD) is a chronic

More information

The Maudsley Prescribing Guidelines in

The Maudsley Prescribing Guidelines in The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief

More information

Mental Health DNA Insight WHITE PAPER

Mental Health DNA Insight WHITE PAPER Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,

More information

foreword general general Six Persimmons 六柿圖 other modalities of treatments by evidence or impression? anxiety disorders drugs benzodiazepines

foreword general general Six Persimmons 六柿圖 other modalities of treatments by evidence or impression? anxiety disorders drugs benzodiazepines Clinical Updates Management of Anxiety Disorders John So - Psychiatrist foreword Six Persimmons 六柿圖 MuqiFachang 牧谿法常 after Zen meditation mindfulness other trends of psychotherapy other modalities of treatments

More information

New Patient Questionnaire

New Patient Questionnaire 4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with

More information

Pharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines

Pharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR

More information

Pharmacological Treatment of Anxiety & Depressive Disorders

Pharmacological Treatment of Anxiety & Depressive Disorders Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:

More information

Panic disorder is a chronic and recurrent illness associated

Panic disorder is a chronic and recurrent illness associated CLINICAL PRACTICE GUIDELINES Management of Anxiety Disorders. Panic Disorder, With or Without Agoraphobia Epidemiology Panic disorder is a chronic and recurrent illness associated with significant functional

More information

Medications in Autism: What We Know and Don't Know

Medications in Autism: What We Know and Don't Know Medications in Autism: What We Know and Don't Know Jeremy Veenstra-VanderWeele, M.D. Mortimer D. Sackler, M.D., Associate Professor Center for Autism and the Developing Brain Sackler Institute for Developmental

More information

Mentoring Session: Participant Cases

Mentoring Session: Participant Cases Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants

More information

OHSU Drug Effectiveness Review Project Summary Report Benzodiazepines

OHSU Drug Effectiveness Review Project Summary Report Benzodiazepines Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Effective Health Care

Effective Health Care Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such

More information

Psychiatric Medication Guide

Psychiatric Medication Guide Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants

More information

Major Depressive Disorder (MDD) in Children under Age 6

Major Depressive Disorder (MDD) in Children under Age 6 in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian

More information

Drugs, Society and Behavior

Drugs, Society and Behavior SOCI 270 Drugs, Society and Behavior Spring 2016 Professor Kurt Reymers, Ph.D. Chapter 8 Medication for Mental Disorders 1. Mental Disorders: a. The Medical Model Model: symptoms diagnosis determination

More information

Clinical Guideline for the Management of Bipolar Disorder in Adults

Clinical Guideline for the Management of Bipolar Disorder in Adults Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:

More information

The pharmacological management of anxiety disorders

The pharmacological management of anxiety disorders Stephen Bleakley MRPharmS, MCMHP Review in association with The pharmacological management of anxiety disorders Progress in Neurology and Psychiatry is running a series of articles on the major psychiatric

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize

More information

HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE

HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE HEDIS BEHAVIORAL HEALTH RESOURCE GUIDE What is HEDIS? 3 HEDIS Reference Guide for Behavioral Health 4 Behavioral Health HEDIS Measures 13 WHAT IS HEDIS? HEDIS (Healthcare Effectiveness Data and Information

More information

Professor Tony Holland, Department of Psychiatry, University of Cambridge

Professor Tony Holland, Department of Psychiatry, University of Cambridge INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with

More information

Treating sleep disorders

Treating sleep disorders Treating sleep disorders Sue Wilson Centre for Neuropsychopharmacology Imperial College London sue.wilson@imperial.ac.uk Suggested algorithm for treatment of insomnia Diagnosis of insomnia Associated with

More information

Introduction to psychotropic medications JAYNE CAMPBELL

Introduction to psychotropic medications JAYNE CAMPBELL Introduction to psychotropic medications JAYNE CAMPBELL Introduction Psychotropic medications are prescription drugs that are commonly used to control some symptoms associated with many different types

More information

Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials

Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials SPEAKER NOTES Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials Summarized by Thomas T. Thomas New psychotropic medications are coming on the

More information

Presenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy

Presenter Disclosure. Objectives 6/5/2017. Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Depression, Anxiety, PTSD: A Focus on Pharmacotherapy Robert L Page II, Pharm.D., MSPH, FHFSA, FCCP, FAHA Professor of Clinical Pharmacy Clinical Specialist, Division of Cardiology University of Colorado

More information